Intervention: Catheter ablation (n = 1108) or drug therapy (n = 1096). Catheter ablation comprised pulmonary vein isolation, with ancillary techniques at the discretion of an experienced physician. In the drug therapy group, it was recommended that patients receive rate-control medications first; rhythm-control drug therapy could be initiated in patients in whom rate-control therapy had previously failed. All patients were to receive anticoagulation in accordance with contemporaneous guidelines; patients who had ablation were supplemented with anticoagulation for ≥ 3 months.
Outcomes: A composite of death, disabling stroke, serious bleeding, or cardiac arrest. Secondary outcomes included components of the primary outcome and a composite of death or cardiovascular hospitalizations. The primary composite was initially a secondary outcome but that was changed to the primary outcome when it became evident that, due to slow recruitment and lower-than-expected rates of death, the study would be underpowered for the original primary outcome of all-cause mortality. 2200 patients would provide 90% power to detect a 30% relative reduction in the primary outcome assuming a 25% cross-over from drug therapy to ablation (2-sided ␣ = 0.05).
Patient follow-up: 89% (intention-to-treat analysis).

Main results
The results are in the Table.
Conclusion
In patients with symptomatic atrial fibrillation, catheter ablation did not reduce a composite of cardiovascular events and mortality compared with drug therapy. 
*
Commentary
AF is the most common cardiac arrhythmia, and its incidence increases with advancing age. AF is predicted to affect 12 million people in the USA and 17.9 million in Europe within the next 3 decades (1). Analyses from the Centers for Disease Control and Prevention estimate that AF costs about $6 billion/y in the USA (2) .
The analysis of the CABANA trial by Packer and colleagues showed that invasive ablation (pulmonary vein isolation with additional ablation procedures at the discretion of investigators) did not reduce risk for a composite of death, cardiac arrest, stroke, or serious bleeding, nor did it reduce all-cause mortality, compared with pharmacologic therapy (rhythm-or rate-control drugs) over a median of 49 months in patients with symptomatic AF. Notably, 19% of patients randomly assigned to catheter ablation needed ≥ 1 repeated procedure, even though the physicians had done ≥ 100 cases.
An important secondary endpoint in the trial was AF recurrence, which was reduced by 48% in the ablation group compared with the medical treatment group. The analysis of CABANA by Mark and colleagues showed that catheter ablation improved QoL more than pharmacologic therapy at 12 months, a finding confirmed in the smaller (155 AF patients), unblinded, Scandinavian CAPTAF trial. However, it is evident that patients who are pharmacologically treated for AF will also have improved QoL (3) with no increased risk for death or stroke, the most concerning complications of AF.
CABANA was complicated by many crossovers. 28% of patients in the drug therapy group had ablation, 9.2% of patients assigned to ablation did not actually have it, and 45% received antiarrhythmic drugs during the postblanking period. In addition to the primary intention-to-treat analysis, in which patients were analyzed in their assigned groups regardless of their actual treatment, secondary analyses were performed. Both Follow-up period: Up to 6 years.
(continued on page JC9)
Catheter ablation vs drug therapy in patients with symptomatic atrial fibrillation †
Setting: 126 clinical centers in 10 countries.
Patients: 2204 adults who were ≥ 65 years of age or < 65 years of age with ≥ 1 risk factor for stroke (median age 68 y, 63% men) {and had ≥ 2 paroxysmal AF episodes ≥ 1 hour in duration or electrocardiographic documentation of 1 persistent or longstanding persistent AF episode within the past 6 months, and warranted active therapy. Exclusion criteria included failure of ≥ 2 antiarrhythmic drugs and previous left atrial catheter ablation for AF}*.
Intervention: Catheter ablation (n = 1108) or drug therapy (n = 1096). Catheter ablation comprised pulmonary vein isolation, with ancillary techniques at the discretion of an experienced physician. {In the drug therapy group, it was recommended that patients receive rate-control medications first; rhythm-control drug therapy could be initiated in patients in whom rate-control therapy had previously failed. All patients were to receive anticoagulation in accordance with contemporaneous guidelines; patients who had ablation were supplemented with anticoagulation for ≥ 3 months.}* Outcomes: Primary QoL outcomes were the Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire scores and modified Mayo AF-Specific Symptom Inventory (MAFSI) frequency and severity scores at 12 months. Secondary outcomes included the primary outcomes at 3 months.
Patient follow-up: 81% to 89% for the AFEQT at 3 and 12 months and mMAFSI at 3 months (intention-to-treat analysis).
Main results
The results for QoL outcomes with ≥ 80% follow-up are in the Table.
Conclusion
In patients with symptomatic atrial fibrillation, catheter ablation improved quality of life at 12 months compared with drug therapy. 
Commentary (continued from page JC8)
on-treatment analyses (based on the treatments patients received) and per protocol analyses (only patients who followed the trial protocol) showed that ablation reduced the primary composite outcome compared with medical treatment, but both of these analyses are subject to bias.
The results of the CABANA trial may also be affected by the lower-than-expected rates of mortality (about 5.4%) and disabling stroke (0.7%) at 4 years in the medical therapy group. This shows the outstanding results achieved by current pharmacologic management of AF (4, 5).
A previous clinical trial in a highly selected population of patients with symptomatic AF, heart failure, and reduced ejection fraction showed that ablation decreased all-cause mortality (6) . On the other hand, an observational study conducted in parallel to CABANA to assess its generalizability showed that catheter ablation and medical therapy did not differ for the composite outcome of death, cardiac arrest, stroke, or major bleeding in patients < 65 years without stroke risk factors (excluded from CABANA) (7 Catheter ablation improved quality of life more than drug therapy at 1 y in symptomatic atrial fibrillation Clinical impact ratings: ૺૺૺૺૺ૾૾ ૺૺૺૺૺ૾૾
Question
In patients with symptomatic atrial fibrillation (AF), does catheter ablation improve quality of life (QoL) more than drug therapy? Patients: 155 adults 30 to 70 years of age (mean age 56 y, 77% men) who had a history of symptomatic AF for ≥ 6 months with electrocardiographic verification in the past 12 months; ≥ 1 paroxysmal AF episode in the past 2 months or 2 persistent AF episodes converted to sinus rhythm in the past 12 months; and failure of, or intolerance to, ≤ 1 antiarrhythmic drug (including ␤-blockers) as well as completion of a 2-month run-in period. Exclusion criteria included New York Heart Association class III or IV, left ventricular ejection fraction < 35%, left atrial diameter > 60 mm, ventricular pacing dependency, or past AF ablation.
Methods
Design
Intervention: Catheter ablation (n = 79) or drug therapy (n = 76). Catheter ablation comprised circumferential pulmonary vein isolation with an optional left atrial roof line in patients with persistent AF and for reablations. Ablation was supplemented with oral anticoagulation for ≥ 4 weeks before and 3 months after ablation; antiarrhythmic medication was administered for 3 months after ablation. Reablation was allowed 3 months after the initial procedure. In the drug therapy group, patients were treated with antiarrhythmic medications, with a change of drug allowed after 1 month (3 mo for amiodarone) as indicated by symptoms.
Outcomes: 36-Item Short-Form Health Survey (SF-36) General Health subscale score at 12 months. Secondary outcomes included the other 7 SF-36 subscales at 12 months.
Patient follow-up: 94% at 12 months (intention-to-treat analysis).
Main results
Conclusion
*
